Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29682808 | 0.79 | HTR3A (0.37) | CYP2A6TRPV4PARP1MAPT | |
| SCHEMBL21046810 | 0.79 | HTR3A (0.37) | CYP2A6TRPV4PARP1MAPT | |
| SCHEMBL31172543 | 0.78 | PTGS1 (0.34) | CYP2A6KDM4EPARP1HTR6MAPT | |
| SCHEMBL29469917 | 0.78 | NPSR1 (0.36) | PARP1MAPT | |
| SCHEMBL743679 | 0.78 | NPSR1 (0.36) | PARP1MAPT | |
| SCHEMBL31553890 | 0.78 | PARP1 (0.51) | PARP1 | |
| SCHEMBL31172611 | 0.74 | MAPT (0.36) | TRPV4TSHRPARP1MAPTL3MBTL1 | |
| SCHEMBL5308756 | 0.71 | PTGS2 (0.47) | SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL4648923 | 0.71 | PARP1 (0.42) | CYP2A6KDM4EGAASMN1; SMN2DRD2 | |
| SCHEMBL25046178 | 0.71 | TRPV4 (0.44) | TRPV4KDM4EGAATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122182-A1 | MYST Inhibitors | Isosterix, Inc. | 2025-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122182-A1 | MYST Inhibitors | MNAT1, SUGT1, ACAT2 | CYP2A6 4365/4885TRPV4 4752/4885KDM4E 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.